{"id":35371,"date":"2015-04-30T06:47:51","date_gmt":"2015-04-30T10:47:51","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=35371"},"modified":"2015-04-30T06:47:51","modified_gmt":"2015-04-30T10:47:51","slug":"celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371","title":{"rendered":"Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Celgene Corporation (NASDAQ:CELG)<\/strong> is deepening its ties with biotech company <strong>Agios Pharmaceuticals Inc (NASDAQ:AGIO)<\/strong> with a 50-50 collaboration on another preclinical cancer candidate.<\/p>\n<p style=\"text-align: justify;\">Celgene will give $10 million up front and promises up to $70 million more to get a share of AG-881. AG-881 is Agios\u2019 therapy that aims to target cancer metabolism with the goal of killing tumours. The therapy has successfully passed the blood brain barrier in preclinical trials and has successfully reached to cancers showing certain mutations. With the partnership with Celgene in place, Agios can expect to get the therapy into clinical trials next quarter.<\/p>\n<p style=\"text-align: justify;\">AG-881 is a molecule that can fully penetrate the blood brain barriers and inhibit isocitratedehydrogenase-1 (DH1) and IDH2 mutation in cancer models. The testing is only in the preclinical stage.<\/p>\n<p style=\"text-align: justify;\">Under the collaboration, the two companies will share the development costs equally, and the profits will also be split down the middle. Celgene will handle the global sales while Agios will handle the sales in America.<\/p>\n<p style=\"text-align: justify;\">This is the third collaboration between the two companies. The relationship began with the $120 million deal for cancer treatment AG221 in 2010. The next deal was on AG-120, which also targeted tumours with IDH mutation. Under the deal, Agios will get up to $240 million in milestone payment.<\/p>\n<p style=\"text-align: justify;\">Agios\u2019 CEO David Schenkein stated that AG-881 adds to the company\u2019s portfolio on IDH inhibitors as it has a unique profile. He further stated that the therapy has the potential to support the company\u2019s efforts to develop treatment options to patients with giloma. The drug could also be the second generation molecule for both AG-120 and AG-221.<\/p>\n<p style=\"text-align: justify;\">Agios Pharmaceuticals Inc (NASDAQ:AGIO) has been on the rise since raising an IPO of $106 million during the early days of biotech boom. Celgene meanwhile is a drug company with many drugs under its portfolio. Celgene has repeatedly shown faith in Agios\u2019 technology and the leadership of Schenkein.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Celgene Corporation (NASDAQ:CELG) is deepening its ties with biotech company Agios Pharmaceuticals Inc (NASDAQ:AGIO) with a 50-50 collaboration on another preclinical cancer candidate. Celgene will [&hellip;]<\/p>\n","protected":false},"author":6,"featured_media":18676,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[264],"tags":[11299,2860,11340,11300,2861],"stock_ticker":[],"class_list":["post-35371","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health","tag-agios-pharmaceuticals-inc-nasdaqagio","tag-celgene-corporation-nasdaqcelg","tag-david-schenkein","tag-nasdaqagio","tag-nasdaqcelg","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Celgene Corporation (NASDAQ:CELG) is deepening its ties with biotech company Agios Pharmaceuticals Inc (NASDAQ:AGIO) with a 50-50 collaboration on another preclinical cancer candidate. Celgene will [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2015-04-30T10:47:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"870\" \/>\n\t<meta property=\"og:image:height\" content=\"768\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Brendan Byrne\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Brendan Byrne\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371\"},\"author\":{\"name\":\"Brendan Byrne\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\"},\"headline\":\"Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time\",\"datePublished\":\"2015-04-30T10:47:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371\"},\"wordCount\":334,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg\",\"keywords\":[\"Agios Pharmaceuticals Inc (NASDAQ:AGIO)\",\"Celgene Corporation (NASDAQ:CELG)\",\"David Schenkein\",\"NASDAQ:AGIO\",\"NASDAQ:CELG\"],\"articleSection\":[\"Health\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371\",\"name\":\"Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg\",\"datePublished\":\"2015-04-30T10:47:51+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg\",\"width\":870,\"height\":768},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511\",\"name\":\"Brendan Byrne\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g\",\"caption\":\"Brendan Byrne\"},\"description\":\"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371","og_locale":"en_US","og_type":"article","og_title":"Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time - Wall Street PR","og_description":"Celgene Corporation (NASDAQ:CELG) is deepening its ties with biotech company Agios Pharmaceuticals Inc (NASDAQ:AGIO) with a 50-50 collaboration on another preclinical cancer candidate. Celgene will [&hellip;]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2015-04-30T10:47:51+00:00","og_image":[{"width":870,"height":768,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg","type":"image\/jpeg"}],"author":"Brendan Byrne","twitter_misc":{"Written by":"Brendan Byrne","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371"},"author":{"name":"Brendan Byrne","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511"},"headline":"Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time","datePublished":"2015-04-30T10:47:51+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371"},"wordCount":334,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg","keywords":["Agios Pharmaceuticals Inc (NASDAQ:AGIO)","Celgene Corporation (NASDAQ:CELG)","David Schenkein","NASDAQ:AGIO","NASDAQ:CELG"],"articleSection":["Health"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371","url":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371","name":"Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg","datePublished":"2015-04-30T10:47:51+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2014\/04\/celgene-corporation.jpg","width":870,"height":768},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/celgene-corporation-nasdaqcelg-and-agios-pharmaceuticals-inc-nasdaqagio-tie-up-for-the-third-time-35371#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Celgene Corporation (NASDAQ:CELG) and Agios Pharmaceuticals Inc (NASDAQ:AGIO) Tie Up for the Third Time"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/63a75bf2d685d9d351a6f01cfc69b511","name":"Brendan Byrne","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/c07a17b7438044417a1ad0f7933a311fcc2a96eaf4b15f2599b0fdfb37cbda41?s=96&d=mm&r=g","caption":"Brendan Byrne"},"description":"While studying economics, Brendan found himself comfortably falling down the rabbit hole of restaurant work, ultimately opening a consulting business and working as a private wine buyer. On a whim, he moved to China, and in his first week following a triumphant pub quiz victory, he found himself bleeding on the floor based on his arrogance. The same man who put him there offered him a job lecturing for the University of Wales in various sister universities throughout the Middle Kingdom. While primarily lecturing in descriptive and comparative statistics, Brendan simultaneously earned an Msc in Banking and International Finance from the University of Wales-Bangor. He's presently doing something he hates, respecting French people. Well, two, his wife and her mother in the lovely town of Antigua, Guatemala. You may contact Brendan via his email (brendanbyrne@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/u\/0\/116608759701551457422).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/brendan-byrne"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35371","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=35371"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/35371\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/18676"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=35371"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=35371"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=35371"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=35371"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}